| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Schnurri-3 inhibitor-1 targets schnurri-3 (Shn3), a key regulator of adult bone formation. Shn3 is involved in the regulation of osteoblast differentiation and bone remodeling. By inhibiting Shn3, the compound modulates bone formation pathways. The compound's mechanism involves inhibition of Shn3 protein expression through the EF1alpha promoter in osteoblast cells. This makes Schnurri-3 inhibitor-1 a valuable tool for studying bone biology and potential therapeutic applications for bone-related disorders.
|
|---|---|
| ln Vitro |
In an SV40 large T antigen-transformed osteoblast cell line (Clone20-Shn3FFL), Schnurri-3 inhibitor-1 (0-50 μM; 24 hours) suppresses Shn3 with the EF1α promoter, with an AC50 value of 2.09 μM [1]. With an AC50 value of 54.73 μM, Schnurri-3 inhibitor-1 (0.195-26 μM; 48 hours) demonstrates modest action in HepG2 mammalian cells [1]. Determination of cell viability [1]
In vitro, Schnurri-3 inhibitor-1 has demonstrated activity in osteoblast cell lines. In the Shn3FFL osteoblast cell line, the compound inhibits Shn3 protein expression via the EF1alpha promoter with an AC50 of 2.09 μM. In HepG2 mammalian cells, the compound shows moderate activity with an AC50 of 54.73 μM. The compound (0-50 μM; 24 h) can inhibit Shn3 in osteoblast cell lines transformed with SV40 large T antigen (Clone20-Shn3FFL). These in vitro findings support the compound's role as a Shn3 inhibitor. |
| ln Vivo |
In vivo, Schnurri-3 inhibitor-1 is being investigated for its potential in osteoporosis research. As a Shn3 inhibitor, it may promote bone formation by modulating osteoblast differentiation. The compound's in vivo effects are mediated through the inhibition of Shn3, which is an essential regulator of adult bone formation. Further studies in animal models are needed to confirm its in vivo efficacy and safety. The compound is currently in the research phase.
|
| Enzyme Assay |
In vitro assays for Schnurri-3 inhibitor-1 typically involve measuring the inhibition of Shn3 protein expression in osteoblast cell lines. The Shn3FFL cell line, which contains an EF1alpha promoter-driven reporter, is used to assess Shn3 inhibition. Cells are treated with varying concentrations of the compound (e.g., 0.195-26 μM) for 48 hours. Shn3 expression is measured using reporter assays or Western blotting. The AC50 value, representing the concentration required for 50% inhibition, is calculated from the dose-response curve. The compound is typically dissolved in DMSO for stock solutions and diluted in cell culture medium.
|
| Cell Assay |
Cell viability determination [1]
Cell Types: Clone20-Shn3FFL Cell Tested Concentrations: 2.09 μM Incubation Duration: 24 hrs (hours) Experimental Results: The AC50 value of the active concentration is 2.09 μM. Cell viability assay [1] Cell Types: Clone20-Shn3FFL Cell Tested Concentrations: 1.2 μM Incubation Duration: 24 hrs (hours) Experimental Results: The AC50 value of the active concentration is 1.2 μM. In vitro cell-based assays for Schnurri-3 inhibitor-1 are performed in osteoblast cell lines such as Shn3FFL and Clone20-Shn3FFL. Cells are seeded in multi-well plates and treated with varying concentrations of the compound (0-50 μM) for 24-48 hours. Shn3 protein expression is measured by Western blotting or reporter assays. Cell viability is assessed to ensure the compound is not cytotoxic at the concentrations used. The compound is typically dissolved in DMSO and diluted in cell culture medium. The compound's effects on osteoblast differentiation and bone formation markers can also be studied. |
| Animal Protocol |
Specific in vivo animal experiment protocols for Schnurri-3 inhibitor-1 are not detailed in the available literature. However, as a potential therapeutic agent for osteoporosis, it would likely be tested in animal models of bone loss. The compound could be administered orally or intraperitoneally to ovariectomized mice or other models of osteoporosis. Bone mineral density, bone formation rates, and other bone parameters would be measured to assess efficacy. The route of administration and dosing would depend on the specific experimental design.
|
| ADME/Pharmacokinetics |
Schnurri-3 inhibitor-1 has a molecular weight of 284.28 g/mol and the formula C12H10F2N2O2S. The compound is soluble in DMSO at 50 mg/mL. For storage, the powder is kept at -20°C for up to 3 years. In solvent, it is stored at -80°C for up to 1 year. The compound appears as a yellow solid. Its purity is typically high (e.g., 99.97%). The compound is shipped at room temperature or with blue ice.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for Schnurri-3 inhibitor-1 are not provided in the available sources. As a research chemical, its safety profile in humans has not been established. The compound is classified as a research reagent and is not for therapeutic or veterinary use. Standard laboratory safety precautions should be followed when handling this compound, including the use of appropriate personal protective equipment. Its purity is typically ≥98%.
|
| References | |
| Additional Infomation |
Schnurri-3 inhibitor-1 (CAS 736154-60-2) is a potent inhibitor of schnurri-3 (Shn3), an essential regulator of adult bone formation. It has the molecular formula C12H10F2N2O2S and a molecular weight of 284.28 g/mol. The compound inhibits Shn3 protein expression via the EF1alpha promoter in the osteoblast cell line Shn3FFL with an AC50 of 2.09 μM. It has research value in osteoporosis. The compound is soluble in DMSO at 50 mg/mL and is stored at -20°C. Schnurri-3 inhibitor-1 is intended for research use only.
|
| Molecular Formula |
C12H10F2N2O2S
|
|---|---|
| Molecular Weight |
284.281808376312
|
| Exact Mass |
284.043
|
| CAS # |
736154-60-2
|
| PubChem CID |
2473445
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
1.5
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
19
|
| Complexity |
380
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1(S(NCC2C=CN=CC=2)(=O)=O)=CC=C(F)C(F)=C1
|
| InChi Key |
BMPWOBNXZUHLQC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H10F2N2O2S/c13-11-2-1-10(7-12(11)14)19(17,18)16-8-9-3-5-15-6-4-9/h1-7,16H,8H2
|
| Chemical Name |
3,4-difluoro-N-(pyridin-4-ylmethyl)benzenesulfonamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~879.41 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (7.32 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.32 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (7.32 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5177 mL | 17.5883 mL | 35.1766 mL | |
| 5 mM | 0.7035 mL | 3.5177 mL | 7.0353 mL | |
| 10 mM | 0.3518 mL | 1.7588 mL | 3.5177 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
